Trifocal technology IOLs to correct refractive defects and presbyopia after cataract surgery

Session Details

Session Title: Presented Poster Session: EDOF IOLs

Venue: Poster Village: Pod 1

First Author: : M.Piovella ITALY

Co Author(s): :    B. Kusa                       

Abstract Details

Purpose:

Trifocal Technology IOLs to Correct Refractive Defects and Presbyopia After Cataract Surgery

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza – Italy

Methods:

290 Eyes with cataract were implanted with trifocal IOLs . 148 Eyes of 91 patients (mean age: 67.96 ± 11.11 yrs) had AT LISA tri 839 MP trifocal IOL (Carl Zeiss Meditec)142 eyes of 86 patients (mean age: 66.93 ± 11.64 yrs) with corneal astigmatism (1.46 ± 0.53 D) had AT LISA tri toric 939MP implantation. IOL calculations were performed using IOL MASTER® 700. Toric IOL axis alignment was performed using Callisto eye® system. Outcomes measurements were subjective refraction, corneal astigmatism, visual acuity for distance (4m) intermediate (70 cm) and near (40cm), and contrast sensitivity using Stereo Optical OPTEC 6500

Results:

At 4 years, in patient with AT LISA tri 839 MP trifocal IOL monocular UCDVA was 20/23 ± 25.40. Monocular intermediate vision was 20/32 In patient with toric trifocal IOLs mean monocular UCDVA and BCDVA were 20/22 ± 3.25 and 20/20 ± 2.16 respectively for far vision. Intermediate monocular UCVA was 20/31 ± 4.75. Near monocular UCVA was 20/27 ± 2.56.The mean residual refractive cylinder was 0.46 ± 0.40. In 138 patients binocular results UCDVA was 20/17, intermediate 20/29 and near vision 20/25. Photopic contrast sensitivity were within the normal range for lower spatial frequencies in both groups

Conclusions:

AT LISA tri toric 939MP and AT LISA tri 839 MP are an advanced generation multifocal IOL. Clinical outcomes indicate that this is an effective multifocal design to correct refractive defects and to achieve presbyopia after cataract surgery

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented